More than 13 years after its initial FDA approval, Pfizer’s blood cancer drug Adcetris has nabbed another regulatory green ...

Despite research showing the benefits of circulating tumor DNA as an indicator of disease remission in B-cell lymphoma, ...

米托蒽醌作为 Usp11 的抑制剂，给予野生型小鼠米托蒽醌处理后进行 TBI，结果显示米托蒽醌干预使 Usp11+/+ 小鼠脾脏边缘区变窄，减轻了电离辐射后 MZ B 细胞数量的减少。流式细胞术分析表明，米托蒽醌处理后，Usp11+/+ 小鼠受 TBI 后 MZ B 细胞的总百分比显著高于 PBS 处理组，且血清 IgM 水平变化表明米托蒽醌干预减少了抗体类型的转变。这说明靶向 Usp11 ...

Fate Therapeutics uses iPSC and gene editing to offer scalable off-the-shelf therapies. Read more to see why I rate FATE ...

Researchers have identified a method to enhance the effectiveness of a promising cancer treatment. They found that modifying a specific gene improves the ability of immune cells to combat cancer for ...

A breakthrough CAR-T cell therapy, Qartemi, has been approved for blood cancer patients in India, offering new hope to those ...